ReviewAmerican heart journal2012
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Review in American heart journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.Neurobiology of stress · 2024Article
- Potential for Prebiotic StabilizedAntioxidants (Basel, Switzerland) · 2022Article
- Review
- The CD36-PPARγ Pathway in Metabolic Disorders.International journal of molecular sciences · 2018Review
- Article
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis.The Journal of clinical investigation · 2017Review
- Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Molecular metabolism · 2017Article
- Recent advances in understanding/managing type 2 diabetes mellitus.F1000Research · 2017Review
- Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells.Iranian journal of basic medical sciences · 2016Article
- Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantia.Journal of clinical and diagnostic research : JCDR · 2016Article
- PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.Alcoholism, clinical and experimental research · 2016Article
- Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.PloS one · 2015Article
- Feed-forward transcriptional programming by nuclear receptors: regulatory principles and therapeutic implications.Pharmacology & therapeutics · 2015Review
- Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs.Frontiers in immunology · 2015Review
- PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.Neuropharmacology · 2014Article
- Something old, something new and something very old: drugs for treating type 2 diabetes.British journal of pharmacology · 2014Review
- Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells.Molecules (Basel, Switzerland) · 2014Article
- Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation.International journal of endocrinology · 2014Review
- Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.Diabetes & metabolism journal · 2013Review
- Cardiometabolic interventions - focus on transcriptional regulators.The European journal of cardiovascular medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator-activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.